Embecta (NASDAQ:EMBC – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Embecta to post earnings of $0.45 per share and revenue of $256.08 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.
Embecta (NASDAQ:EMBC – Get Free Report) last announced its quarterly earnings results on Tuesday, November 26th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.40 by $0.05. Embecta had a negative return on equity of 18.54% and a net margin of 6.97%. The company had revenue of $286.10 million for the quarter, compared to the consensus estimate of $276.97 million. During the same quarter last year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Embecta Stock Down 3.1 %
Shares of EMBC stock opened at $18.40 on Thursday. Embecta has a 12 month low of $9.93 and a 12 month high of $21.48. The business’s 50 day moving average is $19.52 and its two-hundred day moving average is $16.35. The company has a market cap of $1.07 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 1.02 and a beta of 1.23.
Embecta Announces Dividend
Wall Street Analyst Weigh In
Several equities analysts have commented on the company. Morgan Stanley upgraded Embecta from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $13.00 to $20.00 in a report on Monday, December 2nd. BTIG Research upgraded shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Wednesday, November 27th.
View Our Latest Research Report on EMBC
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Read More
- Five stocks we like better than Embecta
- 3 Warren Buffett Stocks to Buy Now
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Steel Stocks Soaring After Tariff Announcements
- Which Wall Street Analysts are the Most Accurate?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.